Rick Barry joined Cassava Sciences as CEO, leading groundbreaking simufilam exploration supported by an animal model study conducted at Yale.
4 reports, 1 independent
Updated Aug 14
Gone quiet
- Reports
- 4
- Developments
- 3
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Rick Barry joined Cassava Sciences as CEO, leading groundbreaking simufilam exploration supported by an animal model study conducted at Yale.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Rick Barry appointed CEO of Cassava Sciences, leading simufilam exploration with Yale.1 source
New collaboration formed for simufilam preclinical study.1 source
Cassava Sciences announces CNS treatment focus and Angélique Bordey's appointment as Senior VP of Neuroscience.1 source
Keep exploring
The entities involved
-
Cassava Sciences
American pharmaceutical company
Nothing else this week.
-
Rick Barry
American basketball player
Nothing else this week.
-
Yale
Canadian political candidate
Coverage
Newest first; wire copies grouped- GlobeNewswireCassava Reports Q2 2025 Financials Results and Provides Business Update Following positive preclinical data, simufilam development to advance with a clinical study expected to begin in H1 2026 for th
- GlobeNewswireCassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer Joseph Hulihan, MD, MSHP, brings substantial clinical development experience advancing novel therapies for TSC-related epilepsy a
- GlobeNewswireCassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy Study in a TSC mouse model further demonstrates simufilam’s anti-seizure activity Study conducted in
- GlobeNewswireCassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable hum